Targeted degradation of EGFR 19Del by PROTACs suppresses tumor growth in non-small-cell lung cancer
With its low molecular weight and excellent in vitro and in vivo efficacy, compound 14 could serve as a promising lead for developing degrader-based therapies targeting mutated EGFR.
Authors
- Xiaofeng Yuan (ORCID: https://orcid.org/0000-0002-4890-4813)
- Q. Li
- Janne Kulpakko
- Shan‐Chwen Chang (ORCID: https://orcid.org/0000-0001-6505-4139)
- Ren Kong (ORCID: https://orcid.org/0000-0001-9010-1750)
- Ying Gao (ORCID: https://orcid.org/0000-0002-0402-2544)
- Wanzhou Zhao
- Yangyang Su (ORCID: https://orcid.org/0000-0002-4960-6332)
- Pei-Chieng Cha (ORCID: https://orcid.org/0000-0002-5718-2824)
- Lianhua Piao (ORCID: https://orcid.org/0000-0001-6350-0932)
- Wangqiu He
Institutions
- Soochow University (CN)
- National Cerebral and Cardiovascular Center (JP)
- Jiangsu University of Technology (CN)
- Kai Biotech (South Korea) (KR)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-24
- DOI
- https://doi.org/10.3389/fphar.2025.1604661
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province